Drug Search Results
More Filters [+]

EPIGALLOCATECHIN-3-GALLATE

Alternative Names: epigallocatechin-3-gallate, epigallocatechin gallate, tea catechin, teavigo, green tea extract, polyphenols, sunphenon, egcg
Latest Update: 2024-09-10
Latest Update Note: News Article

Product Description

Mechanisms of Action: Proteasome Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Lo.Li.Pharma s.r.l
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for EPIGALLOCATECHIN-3-GALLATE

Countries in Clinic: Australia, Italy

Active Clinical Trial Count: 3

Highest Development Phases

Phase 3: Leiomyoma|Myofibroma

Phase 1: COVID-19|Male Breast Cancer|Triple Negative Breast Cancer

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

DELPHYS PLUS

P3

Recruiting

Myofibroma|Leiomyoma

2025-07-01

66%

DELPHYS PLUS

P3

Recruiting

Myofibroma|Leiomyoma

2025-07-01

66%

DELPHYS PLUS

P3

Recruiting

Myofibroma|Leiomyoma

2025-07-01

66%

DELPHYS PLUS

P3

Recruiting

Myofibroma|Leiomyoma

2025-07-01

66%

Amr Ahmed

P1

Not yet recruiting

Triple Negative Breast Cancer|Male Breast Cancer

2023-12-31

ACTRN12622000284763

P1

Not yet recruiting

COVID-19

None

Recent News Events